SimianX AI LogoSimianX AI

Asset profile

vusolimogene oderparepvec-wtpg · Replimune (REPL)

Indication
advanced refractory melanoma
Also known as
TUDRIQEV, RP1, VO
CompanyREPLReplimune

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietar…

Start live analysis of REPLRun 8-agent AI analysisStock overview

On the calendar

Timeline

Newest first.

Registered trials

Registry IDPhaseStatusPrimary completionEnrollmentSites
NCT04700072Phase 1/2CompletedOct 17, 2025569 of 36 sites in the United States

More from Replimune

Other drugs and candidates from the same company tracked in this sector.

RP1anti-PD-1 failed melanomavusolimogene oderparepvecadvanced melanoma in patients who have progressed on prior anti-PD-1 therapy